4D Molecular (FDMT) news
Recent news
4D Molecular 2Q loss/share $1.04 vs. loss/share 98c y/y
AInvest Wire · Aug 13, 20264D Molecular Therapeutics Q2 revenue USD 3.781 million vs. IBES estimate USD 3.1 million
AInvest Wire · Aug 13, 20264D Molecular Therapeutics Inc: B. Riley initiates coverage with buy rating; target price $37
B. Riley Securities has initiated coverage of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) with a "Buy" rating and a target price of $37 per share, signaling optimism about the company’s long-term potential. 4D Molecular Therapeutics, a clinical-stage biotechnology firm, is focused on developing…
AInvest Wire · Jul 31, 20264D Molecular Therapeutics - 4Front-2 52-week topline data expected in H2 2027
AInvest Wire · Jun 29, 20264D Molecular Therapeutics - 4Front-2 over-enrolled with anticipated n>500; final randomization expected in Q3 2026
4D Molecular Therapeutics (Nasdaq: FDMT) has reported that its global Phase 3 clinical trial, 4FRONT-2, for 4D-150 in the treatment of wet age-related macular degeneration (wet AMD) has exceeded initial enrollment expectations. As of June 2026, the trial has randomized more than 500 patients, with…
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.